Mutant proteases and uses thereof
AssigneeBoard of Regents, The University of Texas System
InventorsBrent IVERSON, Carl DENARD
Life of this patent
Estimating the term…
Abstract
The present disclosure, in some aspects, provides mutant TEV proteases that exhibit improved activity, where the mutant TEV exhibits increase efficiency and/or an increased Kcat for cleavage of an amino acid sequence, and TEV proteases are commonly used for laboratory methods including cleaving fusion proteins and removing a purification tag, such as a maltose binding protein or a poly-histidine tag, from a fusion protein or an antibody.
Claims32
A polypeptide comprising an active mutant TEV (Tobacco Etch Virus) protease, wherein the mutant TEV protease comprises:
- (i) substitution mutations at amino acid residues corresponding to amino acids S3, P8, S31, and A231 of SEQ ID NO:1;
- and/or
- (ii) a substitution mutation of arginine at amino acid residue corresponding to S219 of SEQ ID NO:1.
(canceled)
9-11. (canceled)
14-15. (canceled)
The polypeptide of claim 15, wherein the mutant TEV protease has an amino acid sequence at least 95% identical to (SEQ ID NO:1), and wherein the mutant TEV protease comprises substitution mutations at the amino acid residues corresponding to positions S3I, P8Q, S31T, T173A, and A231V of (SEQ ID NO:1).
17-18. (canceled)
21-23. (canceled)
27-28. (canceled)
30-31. (canceled)
33-36. (canceled)
38-39. (canceled)
42-50. (canceled)
52-54. (canceled)
Dependencies are inferred from the claim text.